Comparative Pharmacology
Head-to-head clinical analysis: NORDITROPIN versus SEROSTIM LQ.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORDITROPIN versus SEROSTIM LQ.
NORDITROPIN vs SEROSTIM LQ
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Human growth hormone (hGH) binds to growth hormone receptors on target cells, activating JAK2/STAT5 signaling pathway, which stimulates insulin-like growth factor 1 (IGF-1) production in the liver and other tissues, promoting linear growth and anabolic effects.
Recombinant human growth hormone (somatropin) that binds to growth hormone receptors, activating JAK-STAT signaling pathways, leading to increased insulin-like growth factor-1 (IGF-1) production, which promotes linear growth and anabolic effects.
0.2-0.3 mg/kg/week subcutaneously divided into 6-7 daily doses; maximum 0.7 mg/kg/week
0.2 mg/kg subcutaneously once daily for 4 weeks in HIV-associated wasting; for growth hormone deficiency, 0.005 mg/kg subcutaneously once daily initially, titrated to 0.01 mg/kg once daily.
None Documented
None Documented
IV: 0.5-1.5 hours (initial), 3-5 hours (terminal); SC: 2-4 hours (mean 3.5 hours). Clinical context: Short half-life necessitates daily dosing; terminal half-life reflects slow absorption from SC depot.
2.6 hours (subcutaneous administration); terminal half-life is approximately 2-3 hours, requiring daily dosing for growth hormone deficiency.
Renal: >90% via glomerular filtration and tubular reabsorption with metabolism in proximal tubules; unchanged drug and metabolites.
Renal: >90% of somatropin is metabolized in the liver and kidneys; less than 1% of the administered dose is excreted unchanged in urine.
Category C
Category C
Growth Hormone
Growth Hormone